NovaThera and Gamida Cell Ltd. Announce a Collaboration Agreement to Develop Cell Therapeutics for Lung Disease
CAMBRIDGE, England & JERUSALEM--(BUSINESS WIRE)--NovaThera and Gamida Cell announced today a collaboration agreement aimed at developing cell therapeutic treatments for lung repair and regeneration. Under the terms of the agreement, NovaThera and Gamida Cell will pool technology and expertise and work together with the clinical team at Papworth Hospital in the U.K. towards advancing cell therapy approaches for treating lung disease. NovaThera specializes in pioneering applications of biomaterials and stem cell biology for regenerative medicine and tissue engineering to provide innovative therapeutic solutions. Gamida Cell develops therapeutics using proprietary technologies that expand populations of hematopoietic stem/progenitor cells such as those derived from cord blood (not the controversial embryonic stem cells), for the treatment of hematological diseases as well as for tissue regeneration applications.